Mark D Bartholomä1, Shaohui Zhang1, Vamsidhar Akurathi1, Christina A Pacak2, Patricia Dunning3, Frederic H Fahey1, Douglas B Cowan2, S Ted Treves4, Alan B Packard5. 1. Division of Nuclear Medicine and Molecular Imaging, Boston Children's Hospital, Boston, MA, 02115, USA; Harvard Medical School, Boston, MA, 02115, USA. 2. Harvard Medical School, Boston, MA, 02115, USA; Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, MA, 02115, USA. 3. Division of Nuclear Medicine and Molecular Imaging, Boston Children's Hospital, Boston, MA, 02115, USA. 4. Harvard Medical School, Boston, MA, 02115, USA; Division of Nuclear Medicine and Molecular Imaging, Brigham & Women's Hospital, Boston, MA, 02115, USA. 5. Division of Nuclear Medicine and Molecular Imaging, Boston Children's Hospital, Boston, MA, 02115, USA; Harvard Medical School, Boston, MA, 02115, USA. Electronic address: alan.packard@childrens.harvard.edu.
Abstract
INTRODUCTION: We recently reported the development of the [(18)F]fluorodiethylene glycol ester of rhodamine B as a potential positron emission tomography (PET) tracer for myocardial perfusion imaging (MPI). This compound was developed by optimizing the ester moiety on the rhodamine B core, and its pharmacokinetic properties were found to be superior to those of the prototype ethyl ester. The goal of the present study was to optimize the rhodamine core while retaining the fluorodiethyleneglycol ester prosthetic group. METHODS: A series of different rhodamine cores (rhodamine 6G, rhodamine 101, and tetramethylrhodamine) were labeled with (18)F using the corresponding rhodamine lactones as the precursors and [(18)F]fluorodiethylene glycol ester as the prosthetic group. The compounds were purified by semipreparative HPLC, and their biodistribution was measured in rats. Additionally, the uptake of the compounds was evaluated in isolated rat cardiomyocytes. RESULTS: As was the case with the different prosthetic groups, we found that the rhodamine core has a significant effect on the in vitro and in vivo properties of this series of compounds. Of the rhodamines evaluated to date, the pharmacologic properties of the (18)F-labeled diethylene glycol ester of rhodamine 6G are superior to those of the (18)F-labeled diethylene glycol esters of rhodamine B, rhodamine 101, and tetramethylrhodamine. As with (18)F-labeled rhodamine B, [(18)F]rhodamine 6G was observed to localize in the mitochondria of isolated rat cardiomyocytes. CONCLUSIONS: Based on these results, the (18)F-labeled diethylene glycol ester of rhodamine 6G is the most promising potential PET MPI radiopharmaceutical of those that have evaluated to date, and we are now preparing to carry out first-in-human clinical studies with this compound.
INTRODUCTION: We recently reported the development of the [(18)F]fluorodiethylene glycol ester of rhodamine B as a potential positron emission tomography (PET) tracer for myocardial perfusion imaging (MPI). This compound was developed by optimizing the ester moiety on the rhodamine B core, and its pharmacokinetic properties were found to be superior to those of the prototype ethyl ester. The goal of the present study was to optimize the rhodamine core while retaining the fluorodiethyleneglycol ester prosthetic group. METHODS: A series of different rhodamine cores (rhodamine 6G, rhodamine 101, and tetramethylrhodamine) were labeled with (18)F using the corresponding rhodamine lactones as the precursors and [(18)F]fluorodiethylene glycol ester as the prosthetic group. The compounds were purified by semipreparative HPLC, and their biodistribution was measured in rats. Additionally, the uptake of the compounds was evaluated in isolated rat cardiomyocytes. RESULTS: As was the case with the different prosthetic groups, we found that the rhodamine core has a significant effect on the in vitro and in vivo properties of this series of compounds. Of the rhodamines evaluated to date, the pharmacologic properties of the (18)F-labeled diethylene glycol ester of rhodamine 6G are superior to those of the (18)F-labeled diethylene glycol esters of rhodamine B, rhodamine 101, and tetramethylrhodamine. As with (18)F-labeled rhodamine B, [(18)F]rhodamine 6G was observed to localize in the mitochondria of isolated rat cardiomyocytes. CONCLUSIONS: Based on these results, the (18)F-labeled diethylene glycol ester of rhodamine 6G is the most promising potential PET MPI radiopharmaceutical of those that have evaluated to date, and we are now preparing to carry out first-in-human clinical studies with this compound.
Authors: Ajay Purohit; Heike Radeke; Michael Azure; Kelley Hanson; Richard Benetti; Fran Su; Padmaja Yalamanchili; Ming Yu; Megan Hayes; Mary Guaraldi; Mikhail Kagan; Simon Robinson; David Casebier Journal: J Med Chem Date: 2008-04-19 Impact factor: 7.446
Authors: Silvia H D Lacerda; Bindu Abraham; Thomas C Stringfellow; Guilherme L Indig Journal: Photochem Photobiol Date: 2005 Nov-Dec Impact factor: 3.421
Authors: Igal Madar; Hayden T Ravert; Yong Du; John Hilton; Lana Volokh; Robert F Dannals; James J Frost; Joshua M Hare Journal: J Nucl Med Date: 2006-08 Impact factor: 10.057
Authors: Jonghye Woo; Balaji Tamarappoo; Damini Dey; Ryo Nakazato; Ludovic Le Meunier; Amit Ramesh; Joel Lazewatsky; Guido Germano; Daniel S Berman; Piotr J Slomka Journal: Med Phys Date: 2011-11 Impact factor: 4.071
Authors: Mark D Bartholomä; Vijay Gottumukkala; Shaohui Zhang; Amanda Baker; Patricia Dunning; Frederic H Fahey; S Ted Treves; Alan B Packard Journal: J Med Chem Date: 2012-12-14 Impact factor: 7.446
Authors: Padmaja Yalamanchili; Eric Wexler; Megan Hayes; Ming Yu; Jody Bozek; Mikhail Kagan; Heike S Radeke; Michael Azure; Ajay Purohit; David S Casebier; Simon P Robinson Journal: J Nucl Cardiol Date: 2007-10-22 Impact factor: 5.952
Authors: Daniel S Berman; Jamshid Maddahi; B K Tamarappoo; Johannes Czernin; Raymond Taillefer; James E Udelson; C Michael Gibson; Marybeth Devine; Joel Lazewatsky; Gajanan Bhat; Dana Washburn Journal: J Am Coll Cardiol Date: 2012-12-19 Impact factor: 24.094
Authors: Kamila Moskowitzova; Borami Shin; Kaifeng Liu; Giovanna Ramirez-Barbieri; Alvise Guariento; David Blitzer; Jerusha K Thedsanamoorthy; Rouan Yao; Erin R Snay; James A H Inkster; Arzoo Orfany; David Zurakowski; Douglas B Cowan; Alan B Packard; Gary A Visner; Pedro J Del Nido; James D McCully Journal: J Heart Lung Transplant Date: 2018-09-28 Impact factor: 10.247
Authors: Kamila Moskowitzova; Arzoo Orfany; Kaifeng Liu; Giovanna Ramirez-Barbieri; Jerusha K Thedsanamoorthy; Rouan Yao; Alvise Guariento; Ilias P Doulamis; David Blitzer; Borami Shin; Erin R Snay; James A H Inkster; Khadija Iken; Alan B Packard; Douglas B Cowan; Gary A Visner; Pedro J Del Nido; James D McCully Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-11-06 Impact factor: 5.464
Authors: Douglas B Cowan; Rouan Yao; Vamsidhar Akurathi; Erin R Snay; Jerusha K Thedsanamoorthy; David Zurakowski; Maria Ericsson; Ingeborg Friehs; Yaotang Wu; Sidney Levitsky; Pedro J Del Nido; Alan B Packard; James D McCully Journal: PLoS One Date: 2016-08-08 Impact factor: 3.240
Authors: Borami Shin; Mossab Y Saeed; Jesse J Esch; Alvise Guariento; David Blitzer; Kamila Moskowitzova; Giovanna Ramirez-Barbieri; Arzoo Orfany; Jerusha K Thedsanamoorthy; Douglas B Cowan; James A Inkster; Erin R Snay; Steven J Staffa; Alan B Packard; David Zurakowski; Pedro J Del Nido; James D McCully Journal: JACC Basic Transl Sci Date: 2019-12-23